$HRTX
Heron Therapeutics Inc

2015 Q3 Form 10-Q Financial Statement

#000119312515282886 Filed on August 07, 2015

View on sec.gov

Income Statement

Concept 2015 Q3 2015 Q2 2014 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.250M $6.839M $4.510M
YoY Change 95.5% 51.64% -3.63%
% of Gross Profit
Research & Development $14.24M $16.18M $14.28M
YoY Change -3.33% 13.28% 35.6%
% of Gross Profit
Depreciation & Amortization $180.0K $170.0K $130.0K
YoY Change 20.0% 30.77% 62.5%
% of Gross Profit
Operating Expenses $22.49M $23.01M $18.79M
YoY Change 18.67% 22.47% 23.54%
Operating Profit -$22.49M -$23.01M -$18.79M
YoY Change 18.67% 22.47%
Interest Expense $242.0K $237.0K $220.0K
YoY Change 8.04% 7.73% -210.0%
% of Operating Profit
Other Income/Expense, Net $118.0K
YoY Change
Pretax Income -$22.67M -$23.11M -$19.01M
YoY Change 18.13% 21.57% 23.36%
Income Tax
% Of Pretax Income
Net Earnings -$22.67M -$23.11M -$19.01M
YoY Change 18.12% 21.55% 23.37%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$633.8K -$744.5K -$783.3K
COMMON SHARES
Basic Shares Outstanding 35.69M
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q3 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $153.0M $171.5M $105.0M
YoY Change 77.49% 63.33% 201.72%
Cash & Equivalents $153.0M $171.5M $105.0M
Short-Term Investments
Other Short-Term Assets $2.000M $1.900M $500.0K
YoY Change -33.33% 280.0% 25.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $155.0M $173.4M $105.5M
YoY Change 73.76% 64.38% 199.72%
LONG-TERM ASSETS
Property, Plant & Equipment $2.982M $2.905M $3.000M
YoY Change 2.83% -3.17% 11.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $174.0K $130.0K $100.0K
YoY Change 74.0% 30.0% 0.0%
Total Long-Term Assets $3.156M $3.035M $3.100M
YoY Change 1.81% -2.1% 6.9%
TOTAL ASSETS
Total Short-Term Assets $155.0M $173.4M $105.5M
Total Long-Term Assets $3.156M $3.035M $3.100M
Total Assets $158.2M $176.5M $108.6M
YoY Change 71.34% 62.48% 185.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.735M $2.987M $1.800M
YoY Change 82.33% 65.94% -66.67%
Accrued Expenses $11.70M $11.70M $7.700M
YoY Change 40.96% 51.95% 120.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.100M $1.900M $1.300M
YoY Change 40.0% 46.15% 62.5%
Total Short-Term Liabilities $16.45M $16.59M $10.80M
YoY Change 45.58% 53.61% 12.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $16.45M $16.59M $10.80M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $16.50M $16.60M $10.80M
YoY Change 46.02% 53.7% 12.5%
SHAREHOLDERS EQUITY
Retained Earnings -$381.6M -$358.9M
YoY Change
Common Stock $359.0K $356.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $141.7M $159.9M $97.80M
YoY Change
Total Liabilities & Shareholders Equity $158.2M $176.5M $108.6M
YoY Change 71.34% 62.48% 185.04%

Cashflow Statement

Concept 2015 Q3 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income -$22.67M -$23.11M -$19.01M
YoY Change 18.12% 21.55% 23.37%
Depreciation, Depletion And Amortization $180.0K $170.0K $130.0K
YoY Change 20.0% 30.77% 62.5%
Cash From Operating Activities -$19.89M -$15.82M -$12.48M
YoY Change 3.38% 26.76% 15.34%
INVESTING ACTIVITIES
Capital Expenditures -$250.0K -$200.0K -$280.0K
YoY Change 212.5% -28.57% 180.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $240.0K
YoY Change
Cash From Investing Activities -$250.0K $40.00K -$280.0K
YoY Change 212.5% -114.29% 180.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.600M 131.8M 60.29M
YoY Change 207.69% 118.53% 100383.33%
NET CHANGE
Cash From Operating Activities -19.89M -15.82M -12.48M
Cash From Investing Activities -250.0K 40.00K -280.0K
Cash From Financing Activities 1.600M 131.8M 60.29M
Net Change In Cash -18.54M 116.0M 47.53M
YoY Change -1.38% 143.99% -537.66%
FREE CASH FLOW
Cash From Operating Activities -$19.89M -$15.82M -$12.48M
Capital Expenditures -$250.0K -$200.0K -$280.0K
Free Cash Flow -$19.64M -$15.62M -$12.20M
YoY Change 2.51% 28.03% 13.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
CY2015Q2 hrtx Accrued Clinical Liabilities
AccruedClinicalLiabilities
6342000
CY2014Q4 hrtx Accrued Clinical Liabilities
AccruedClinicalLiabilities
3811000
CY2011Q3 hrtx Common Shares Registered For Resale In Connection With Convertible Notes
CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes
3500000
CY2011Q2 hrtx Convertible Debt Issuable In Connection With Private Placement
ConvertibleDebtIssuableInConnectionWithPrivatePlacement
4500000
CY2015Q2 hrtx Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
1903000
CY2014Q4 hrtx Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
1598000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
dei Document Type
DocumentType
10-Q
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35685686
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Voluntary Filers
EntityVoluntaryFilers
No
dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
hrtx Debt Instrument Increase Decrease In Unamortized Discount
DebtInstrumentIncreaseDecreaseInUnamortizedDiscount
161000
CY2015Q2 hrtx Impact On Basic And Diluted Net Loss Per Common Share In Dollars Per Share
ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare
0.10
CY2014Q2 hrtx Impact On Basic And Diluted Net Loss Per Common Share In Dollars Per Share
ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare
0.04
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
171526000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72675000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72287000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105012000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
98851000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
32725000
hrtx Impact On Basic And Diluted Net Loss Per Common Share In Dollars Per Share
ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare
0.19
hrtx Impact On Basic And Diluted Net Loss Per Common Share In Dollars Per Share
ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare
0.17
hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
2531000
hrtx Increase Decrease In Clinical Liabilities
IncreaseDecreaseInClinicalLiabilities
1932000
hrtx Stock Issued During Period Shares Stock Options Exercised Net
StockIssuedDuringPeriodSharesStockOptionsExercisedNet
713381
hrtx Stock Issued During Period Shares Stock Options Exercised Net
StockIssuedDuringPeriodSharesStockOptionsExercisedNet
438255
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2987000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2549000
CY2015Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
518424000
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
378007000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3141000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1080000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5691000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4049000
CY2015Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
154000
CY2014Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
142000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
305000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
281000
CY2015Q2 us-gaap Assets
Assets
176456000
CY2014Q4 us-gaap Assets
Assets
76682000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
173421000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
73732000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
356000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
292000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
323000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
239000
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.45
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.52
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2284000
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2731000
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
28358000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y73D
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
118000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6839000
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4512000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12695000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10206000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
438000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
505000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-447000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-731000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
304000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1965000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
838000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-120000
CY2015Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
83000
CY2014Q2 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
78000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
164000
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
155000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
176456000
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76682000
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
16590000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13620000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
134629000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61249000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
58922000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
241000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6306000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2308000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2905000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-290000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-335000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35488000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28189000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
19000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
128205000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2820000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16175000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14279000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30679000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25907000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-358914000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-315237000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-23107000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-19011000
us-gaap Net Income Loss
NetIncomeLoss
-43677000
us-gaap Net Income Loss
NetIncomeLoss
-36549000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
23014000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
18791000
us-gaap Operating Expenses
OperatingExpenses
43374000
us-gaap Operating Expenses
OperatingExpenses
36113000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-23014000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18791000
us-gaap Operating Income Loss
OperatingIncomeLoss
-43374000
us-gaap Operating Income Loss
OperatingIncomeLoss
-36113000
CY2015Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3074000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2931000
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
130000
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
130000
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-93000
CY2014Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-220000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-303000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-436000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
531000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
335000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1895000
CY2014Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1057000
CY2011Q2 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
4300000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
118000
us-gaap Share Based Compensation
ShareBasedCompensation
5691000
us-gaap Share Based Compensation
ShareBasedCompensation
4049000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
345000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
11.30
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
125000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7918000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6985000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.69
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.73
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.84
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
19.13
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y335D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y29D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
504217
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
713000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
159866000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
63062000
us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our critical accounting policies that involve significant judgment and estimates include accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.</div></div></div></div></div></div>
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
31035000
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24266000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30218000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23989000

Files In Submission

Name View Source Status
0001193125-15-282886-index-headers.html Edgar Link pending
0001193125-15-282886-index.html Edgar Link pending
0001193125-15-282886.txt Edgar Link pending
0001193125-15-282886-xbrl.zip Edgar Link pending
d52312d10q.htm Edgar Link pending
d52312dex311.htm Edgar Link pending
d52312dex312.htm Edgar Link pending
d52312dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hrtx-20150630.xml Edgar Link completed
hrtx-20150630.xsd Edgar Link pending
hrtx-20150630_cal.xml Edgar Link unprocessable
hrtx-20150630_def.xml Edgar Link unprocessable
hrtx-20150630_lab.xml Edgar Link unprocessable
hrtx-20150630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending